FibroBiologics, Inc. Common Stock
FBLGNASDAQHealthcare● Active
$0.98
$-0.03(-2.97%)
Market Cap$2054053
P/E Ratio—
52W High$19.8
52W Low$0.952
FibroBiologics, Inc. Common Stock (FBLG) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FBLG · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$1.33
Est. -$1.26 · -5.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS
FBLG reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.82 | — | — | — | — | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$1.26 | -$1.33 | -5.6% | — | — | — |
| ▲ Q1 FY2026 | Feb 24, 2026 | -$1.44 | -$0.98 | +31.9% | — | — | — |
| ▼ Q4 FY2025 | Oct 31, 2025 | -$0.10 | -$0.13 | -30.0% | — | — | — |
| ▼ Q3 FY2025 | Jul 31, 2025 | -$0.11 | -$0.12 | -9.1% | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.10 | -$0.09 | +10.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.10 | -$0.09 | +5.7% | — | — | — |
| — Q4 FY2024 | Nov 12, 2024 | -$0.08 | -$0.08 | +0.0% | — | — | — |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.82
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$1.33
EPS Est.
-$1.26
EPS Surpr.
-5.6%
Revenue
—
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
-$0.98
EPS Est.
-$1.44
EPS Surpr.
+31.9%
Revenue
—
Q4 FY2025
Oct 31, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.10
EPS Surpr.
-30.0%
Revenue
—
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.11
EPS Surpr.
-9.1%
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.10
EPS Surpr.
+10.0%
Revenue
—
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.10
EPS Surpr.
+5.7%
Revenue
—
Q4 FY2024
Nov 12, 2024
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-1.05 | $-1.05 | $-1.05 | 1 |
| Q3 FY2028 | $-0.95 | $-0.95 | $-0.95 | 1 |
| Q2 FY2028 | $-0.88 | $-0.88 | $-0.88 | 1 |
| Q1 FY2028 | $-0.93 | $-0.93 | $-0.93 | 1 |
| Q4 FY2027 | $-0.87 | $-0.87 | $-0.87 | 1 |
| Q3 FY2027 | $-0.78 | $-0.78 | $-0.78 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -5.6% | $1.31 | $1.32 | +0.76% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +31.9% | $5.06 | $5.35 | +5.73% |
| ▼ Q4 FY2025 | Oct 31, 2025 | -30.0% | $7.94 | $7.87 | -0.88% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -9.1% | $12.69 | $12.74 | +0.39% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +10.0% | $19.00 | $18.00 | -5.26% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +5.7% | $20.80 | $20.40 | -1.92% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +0.0% | $69.00 | $63.40 | -8.12% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +0.0% | $74.20 | $74.60 | +0.54% |
Q2 FY2026+0.76%
Report Date
Apr 30, 2026
EPS Beat/Miss
-5.6%
Price Before
$1.31
Price After
$1.32
Q1 FY2026+5.73%
Report Date
Feb 24, 2026
EPS Beat/Miss
+31.9%
Price Before
$5.06
Price After
$5.35
Q4 FY2025-0.88%
Report Date
Oct 31, 2025
EPS Beat/Miss
-30.0%
Price Before
$7.94
Price After
$7.87
Q3 FY2025+0.39%
Report Date
Jul 31, 2025
EPS Beat/Miss
-9.1%
Price Before
$12.69
Price After
$12.74
Q1 FY2025-5.26%
Report Date
Mar 31, 2025
EPS Beat/Miss
+10.0%
Price Before
$19.00
Price After
$18.00
Q1 FY2025-1.92%
Report Date
Mar 27, 2025
EPS Beat/Miss
+5.7%
Price Before
$20.80
Price After
$20.40
Q4 FY2024-8.12%
Report Date
Nov 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$69.00
Price After
$63.40
Q3 FY2024+0.54%
Report Date
Aug 7, 2024
EPS Beat/Miss
+0.0%
Price Before
$74.20
Price After
$74.60
Avg Beat Reaction-1.81%
Avg Miss Reaction+0.09%
Beat Rate5 / 8 quarters
Largest Move-8.12% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FBLG ends December
FibroBiologics, Inc. Common Stock (FBLG) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-1.33 — missing the analyst consensus of $-1.26 by -5.6%. The next FBLG earnings date is expected around September 1, 2026.
Each quarter, investors track FBLG earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FBLG revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FBLG's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FBLG earnings · 5 questionsFibroBiologics, Inc. Common Stock's next earnings report is expected around September 1, 2026. FBLG typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FBLG historically reports after market close (AMC).
FBLG earnings datewhen is FBLG earningsFBLG next earnings datewhen does FBLG report earningsFBLG earnings calendar
▸ Source: FMP · FibroBiologics, Inc. Common Stock SEC filings · US GAAP · FibroBiologics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026